Erschienen in:
01.01.2012 | Letter to the Editor
A new tool for grade II glioma studies: plotting cumulative time with quality of life versus time to malignant transformation
verfasst von:
Emmanuel Mandonnet, Hugues Duffau, Luc Bauchet
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Overall survival (OS) is the gold-standard endpoint when elaborating clinical trials in oncology. However, grade II glioma (GIIG) patients are typically long survivors. This means that clinical trials using OS as endpoint will span over at least 10 years, rendering their practical organization very difficult. Moreover, OS does not hold any information about patient quality of life (QoL). As GIIG affects young adults who are socially and professionally fully functional, any therapy generating poor QoL would be highly questionable. …